title: Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
abstract: OBJECTIVE
  Because of the unique pharmacology and clinical versatility of botulinum toxin (BoNT), particularly BoNT serotype A (BoNTA), a need exists for discussion of the current data on similarities and differences between two BoNTA products, BOTOX and Dysport.
  
  
  METHODS
  We compared the physiochemical and pharmacological properties of BOTOX and Dysport using information from the Summary of Product Characteristics (SmPC) documents from a number of countries around the world.
  
  
  CONCLUSIONS
  Our analysis based on the SmPC documents demonstrated distinct differences in physical characteristics, breadth of approved indications, dosing and administration, and the incidence and severity of adverse events.
  
  
  CONCLUSIONS
  BOTOX and Dysport are not bioequivalent. Many of the differences between BOTOX and Dysport discussed within are probably related to the differences in their physical characteristics.
authors.affiliation: Diamond Headache Clinic Inpatient Unit, Chicago, IL 60657, USA. rich.wenzel@hotmail.com
authors.forename: R
authors.initials: R
authors.lastname: Wenzel
authors.forename: D
authors.initials: D
authors.lastname: Jones
authors.forename: J A
authors.initials: JA
authors.lastname: Borrego
mesh_terms: D001688:Biological Products / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004348:Drug Labeling; D006801:Humans; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D013810:Therapeutic Equivalency
chemical_list: D001688:Biological Products; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A